Meletios A. Dimopoulos

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Meletios A. Dimopoulos, Peter M. Voorhees, Fredrik Schjesvold et al. · New England Journal of Medicine · 2024 · 70 citations

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies

Flora Zagouri, Efstathios Kastritis, Athanasios Zomas et al. · European Journal Of Haematology · 2017 · 46 citations

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma

Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Dimitrios Christoulas et al. · Blood Cancer Journal · 2018 · 36 citations · Full text

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

María‐Victoria Mateos, Jesús F. San Miguel, Michèle Cavo et al. · The Lancet Oncology · 2025 · 11 citations · Full text

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Meletios A. Dimopoulos, Daniel Coriu, Sosana Delimpasi et al. · Blood Advances · 2024 · 10 citations · Full text